What is Zacks Research’s Forecast for EW FY2024 Earnings?

Edwards Lifesciences Co. (NYSE:EW) – Equities research analysts at Zacks Research upped their FY2024 EPS estimates for Edwards Lifesciences in a research note issued on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $2.58 per share for the year, up from their prior forecast of $2.57. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q4 2024 earnings at $0.55 EPS, Q2 2026 earnings at $0.67 EPS, Q3 2026 earnings at $0.71 EPS, Q4 2026 earnings at $0.72 EPS and FY2026 earnings at $2.76 EPS.

Several other equities analysts also recently issued reports on EW. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Morgan Stanley reiterated an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 11th. JPMorgan Chase & Co. raised their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Robert W. Baird cut their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Finally, Oppenheimer restated an “outperform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a report on Thursday, September 12th. Sixteen analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, Edwards Lifesciences has an average rating of “Hold” and an average target price of $79.40.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $74.16 on Friday. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12. The firm has a market capitalization of $43.74 billion, a price-to-earnings ratio of 10.70, a price-to-earnings-growth ratio of 3.61 and a beta of 1.12. The business’s 50 day simple moving average is $71.52 and its 200-day simple moving average is $72.31. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the prior year, the business posted $0.59 EPS. The company’s revenue for the quarter was up 8.9% on a year-over-year basis.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its stake in Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after purchasing an additional 14,610,123 shares during the last quarter. State Street Corp raised its stake in Edwards Lifesciences by 1.0% in the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock valued at $1,733,270,000 after buying an additional 256,538 shares during the period. Geode Capital Management LLC raised its stake in Edwards Lifesciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock valued at $889,050,000 after buying an additional 284,918 shares during the period. Fisher Asset Management LLC lifted its position in shares of Edwards Lifesciences by 9.8% in the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock valued at $599,078,000 after buying an additional 806,705 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Edwards Lifesciences by 1.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,005,789 shares of the medical research company’s stock worth $396,322,000 after acquiring an additional 61,275 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 37,500 shares of company stock worth $2,508,350. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.